Clinical Skin acquires Glytone

Clinical Skin announced on Monday the acquisition of skincare brand Glytone from French pharmaceutical and cosmetics company, Pierre Fabre Laboratories. 

Financial terms of the deal were not disclosed.

The acquisition of Glytone, ​a renowned skincare brand known for its innovative dermatological solutions, reiterates Clinical Skin’s continued commitment to enhancing its product portfolio and expanding its presence in the cosmeceutical skincare industry, according to a press release.

“We are extremely excited to welcome Glytone into the Clinical Skin family,” said Jaime Castle, CEO at Clinical Skin. “This acquisition aligns perfectly with our mission to continue to scale our offering of skincare solutions that are firmly backed by science and innovation. Glytone’s commitment to quality and efficacy complements our own values, and we are excited to work together to further elevate our product offerings.”

Under the helm of Pierre Fabre Laboratories for over 20 years, Glytone has built a reputation for delivering clinically proven skincare formulations designed to address various dermatological concerns, including aging, hyperpigmentation, and the treatment of acne. Since its inception, the skincare brand garnered a loyal customer base and proven a trustworthy product for dermatologists in the United States. 

“We are proud of the legacy we have built at Glytone over the past 2 decades and are confident that joining Clinical Skin’s portfolio will allow the brand to reach new heights,” said Lisa Morris, CEO Pierre Fabre USA.” Hand in hand with Clinical Skin, we will now focus on assuring on a smooth transition of the brand to the benefit of patients and dermatologists alike.”

The global cosmeceuticals market size was estimated to be worth some $56.08 billion in 2022 and is expected to surpass around $128.54 billion by 2032, poised to grow at a compound annual growth rate (CAGR) of 8.7%, according to Precedence Research.